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The dose of hemodialysis and patient mortality. The relationship
between the delivered dose of hemodialysis and patient mortality remains
somewhat controversial. Several observational studies have shown im-
proved patient survival with higher levels of delivered dialysis dose.
However, several other unmeasured variables, changes in patient mix or
medical management may have impacted on this reported difference in
mortality. The current study of a U.S. national sample of 2,311 patients
from 347 dialysis units estimates the relationship of delivered hemodialysis
dose to mortality, with a statistical adjustment for an extensive list of
comorbidity/risk factors. Additionally this study investigated the existence
of a dose beyond which more dialysis does not appear to lower mortality.
We estimated patient survival using proportional hazards regression
techniques, adjusting for 21 patient comorbidity/risk factors with stratifi-
cation for nine Census regions. The patient sample was 2,311 Medicare
hemodialysis patients treated with bicarbonate dialysate as of 12/31/90
who had end-stage renal disease for at least one year. Patient follow-up
ranged between 1.5 and 2.4 years. The measurement of delivered therapy
was based on two alternative measures of intradialytic urea reduction, the
urea reduction ratio (URR) and Kt/V (with adjustment for urea genera-
tion and ultrafiltration). Hemodialysis patient mortality showed a strong
and robust inverse correlation with delivered hemodialysis dose whether
measured by Kt/V or by URR. Mortality risk was lower by 7% (P = 0.001)
with each 0.1 higher level of delivered Kt/V. (Expressed in terms of URR,
mortality was lower by 11% with each 5 percentage point higher URR;P = 0.001). Above a URR of 70% or a Kt/V of 1.3 these data did not
provide statistical evidence of further reductions in mortality. In conclu-
sion, the delivered dose of hemodialysis therapy is an important predictor
of patient mortality. In a population of dialysis patients with a very high
mortality rate, it appears that increasing the level of delivered therapy
offers a practical and efficient means of lowering the mortality rate. The
level of hemodialysis dose measured by URR or Kt/V beyond which the
mortality rate does not continue to decrease, though not well defined with
this study, appears to be above current levels of typical treatment of
hemodialysis patients in the U.S.
The landmark of experimental dialysis studies, the National
Cooperative Dialysis Study (NCDS), was reported in 1983 [1].
This study was and remains the premier scientific effort to
quantify the amount and components of dialysis therapy provided
to a patient and their correlations with patient outcomes. Both the
NCDS and subsequent analyses [2] focused on the serum urea
concentration. One formulation of the dose of dialysis for urea is
the Kt/V where K is the total (dialyzer plus residual renal
Received for publication June 21, 1995
and in revised form February 15, 1996
Accepted for publication February 15, 1996
© 1996 by the International Society of Nephrology
function) urea clearance (mi/mm), t is the duration of the dialysis
treatment (minutes) and V is the patient's urea volume of
distribution or total body water volume (ml). Based on the NCDS
study data, Gotch and Sargent suggested a minimum target Kt/V
of 1.0 (3 times per week) as adequate therapy. When residual
renal function is negligible, total K equals dialyzer K. A related
measurement of dose of dialysis, the urea reduction ratio (URR),
has been utilized by Owen et al [3]. The URR is 1 minus the ratio
of the post-dialysis over the pre-dialysis blood urea nitrogen
(BUN) expressed in percent. Several investigators have shown a
correspondence between Kt/V and URR while some have shown
a mathematical relationship between the two measurements
The relevance and predictive value of either of these blood urea
measurements as indicators of the dose of dialysis therapy is in a
general state of refinement with recent developments pointing
towards a more widespread acceptance of such quantification in
the U.S. [8—10]. The interest in a valid measurement of the
adequacy of delivered dialysis is intensified by the high mortality
rate for dialysis patients, reports that dialysis patient mortality in
the U.S. is higher than in other societies [11, 12], reports of
substantial variation in mortality rates by dialysis unit [13], as well
as evidence that the level of prescribed dialysis treatment is below
"recommended clinical standards" for a substantial fraction of the
U.S. dialysis population [14]. What constitutes an optimal pre-
scription for uremic toxin clearance in the chronic hemodialysis
patient is still controversial.
There have been very few multicenter studies of the adequacy
of dialysis therapy and subsequent mortality in the U.S. or other
countries. Owen et al [3], reporting on the experience in over 400
dialysis units of National Medical Care Inc., have shown that
mortality is lower at higher doses of dialysis, measured as URR.
However, this study did not adjust for comorbid conditions of
patients. This and other recent reports suggest a correlation of
lower mortality with higher dose of hemodialysis therapy [15—19].
The National Institutes of Health funded a multicenter multiyear
prospective randomized trial of the impact of dialysis dose and
dialyzer flux on morbidity and mortality which is currently in
progress.
The current study reports on the dose of delivered hemodialysis
and the correlation of mortality from a national random sample of
over 2,300 Medicare ESRD patients. This historical prospective
study is also unique in the level of detail of measured patient
comorbid conditions determined at the start of the study.
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Methods
Data source
The data used in these analyses originate from the Special
Study of Case Mix Adequacy of the United States Renal Data
System [20], with supplemental information from the USRDS
database.
The goals of this special study included determining the rela-
tionship of dose of dialysis, and dialyzer characteristics on patient
outcomes. A random sample of 7,096 patients, who were alive on
December 31, 1990, was drawn from 523 center hemodialysis
units, with an average of 14 patients per dialysis unit. A systematic
sample of dialysis units was drawn, based on dialysis unit size and
geography from the universe of all Medicare approved dialysis
units, which accounts for over 90% of all chronic dialysis units.
Patients were subsequently randomly selected (proportional to
unit size) from each of the selected units based on the last two
digits of their Social Security Number. The Coordinating Center
of the USRDS did the selection of dialysis units, and personnel of
the 18 ESRD Networks did the random case finding and the
abstraction of patient medical records using a USRDS data
collection form [20]. Data were abstracted during 1992 and early
1993, and included health insurance information, selected patient
comorbid and risk factors, dialysis treatment parameters, psycho-
social information, kidney transplant information and laboratory
data. The end of study completion date was the date on which
each abstraction form was completed for each patient.
The USRDS database (May 31, 1994 HCFA update) was used
to provide additional patient data including race, primary cause of
ESRD, date of first dialysis treatment, date of death, and date of
any transplant. Of the over 7,000 patients sampled in the USRDS
Case Mix Adequacy Study, 6,749 patients (95.1%) were identified
in the USRDS database. Patients not found in the USRDS
database (N = 348) were excluded from the analysis.
To yield a prevalent sample in which residual renal function was
likely minimal or absent, we excluded patients who started dialysis
within 12 months before study start (27%) from this analysis [21].
An additional 2% of patients were deleted, because they recov-
ered renal function, were less than fifteen years old, or because
the start of ESRD date could not be identified. Another 2% of
patients were deleted because their hemodialysis prescription was
not for three treatments per week. The largest exclusion of 32%
was made for patients missing data for estimating dialysis dose
(primarily a post-BUN reading). The 3% of patients treated with
acetate dialysate were also excluded. The final 1% were excluded
because the Kt/V dose was estimated to be less than 0.4 or greater
than 2.0, or because more than half of comorbid conditions were
missing or days alive could not be calculated. The resulting study
sample consisted of 2,311 prevalent patients from 347 different
dialysis units.
Analytical methods
For variables indicating the presence of comorbid conditions,
missing values were coded as not present with a separate binary
for missing comorbid condition(s).
The primary study variable, delivered dose of dialysis, was
measured alternatively by two indicators, both of which are based
on the reduction of urea during the dialysis treatment. The urea
reduction ratio (URR, arbitrarily listed first) is defined as follows:
URR = [1 — (post-BUN/pre-BUN)] * 100%
where BUN is the blood urea nitrogen concentration (BUN) and
post-BUN refers to the end of dialysis treatment and pre-BUN to
the start of the same dialysis treatment.
The alternative measure of dialysis dose Kt/V is the "corrected"
delivered Kt/V [22], defined as follows:
Delivered Kt/V =
[—ln((post-BUN/pre-BUN) — 0.008 * dialysis hours)] +
(4-3.5 * post-BUN/pre-BUN)*(weight loss/post-weight)
where pre- and post-BUN = before and after dialysis BUN,
weight loss = change in weight occurring during the dialysis
session. The mean value of several Kt/V readings (54% were 3 or
more, 46% were 2 or I readings) over a six months period (study
start 3 months for each patient) was used in these calculations.
"Corrected" refers to the adjustment for urea generation and
weight loss during the dialysis treatment [22]. The time of the
post-dialysis urea sample was not clearly specified but assumed to
be immediately following termination of dialysis. Therefore, these
Kt/V values likely represent the so-called "single pooi" kinetics
and do not account for rebound of BUN.
In an analysis of the effect of "skipped" outpatient dialysis
treatments on mortality, the delivered Kt/V value was multiplied
by the fraction of treatments that were not missed during the
month. (Abstractors were instructed not to count missed outpa-
tient treatments due to hospitalization as "skipped" treatments.)
Analyses were adjusted for the covariates listed in Table 1,
except those noted with an asterisk. Demographics, functional
status, dialysis parameters and laboratory data reflect character-
istics at study start date. The comorbid/risk factors were those
present within 10 years prior to diagnosis of ESRD. Comorbid
conditions selected for inclusion were based on the explained
variance of mortality in a prior Special Study of Case Mix Severity
[23] and on clinical judgment.
The primary dependent variable was the time to death mea-
sured in days. Proportional hazards regression techniques [24]
were used to estimate the relationship of dose of dialysis with
all-cause mortality, given patient characteristics and risk factors.
Patients were censored (removed from the analysis alive) at time
of transplantation, 60 days after a switch to peritoneal dialysis, and
at the study completion date (data abstraction date).
The dose of dialysis was evaluated in two separate main
analyses, one being a continuous specification of dose and the
other in a categorical specification of dose. These two main
analyses were performed for the two alternative indicators of
delivered dose, URR and Kt/V for a total of four main analyses.
For ease of reporting, the sensitivity analyses are reported using
the Kt/V specification. Individual components of dialysis including
time, ultrafiltration and treatments per week were evaluated in a
multivariate analysis with URR. The role of a reduction in Kt/V
by skipped dialysis treatments was studied from the information of
missed treatments during the first months of study.
Sensitivity analyses were performed to determine if the extreme
values represented errors in the data. The model evaluated the
relationship between mortality and corrected Kt/V as a continu-
ous variable over different ranges of Kt/V(0.6 to 1.6 and 0.4 to
1.6).
All analyses were adjusted by covariate for time since first
dialysis. We also tested for interactions of time on dialysis with
other demographic characteristics in the main models. An analysis
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Sample"
Analysis" Excluded
Patient characteristics N = 2,311 N = 1,713
Patient demographics
Age at SSD mean in years
Years on dialysis
White %
Black %
Other race %
Male %
Female %
Hispanic %
Anthropometric characteristics mean
Weight kg
Height cm
Body mass index kg/m2"
Primary cause of ESRDC
Diabetes
Hypertension
Glomerulonephritis
Other, includes missing
Comorbid conditions % yes at start of study
Obese
Unable to ambulate independently
Active smoker
Congestive heart failure
Coronary heart disease
Left ventricular hypertrophy
Cardiomegaly by X-ray examination
Neoplasm
Peripheral vascular disease
Laboratory values mean at start of study
Serum albumin g/dl
Cholesterol mg/dl
BUN pre-dialysis, mg/dl"
BUN post-dialysis, mg/di"
Bilirubin mg/dl
Patients' residence by Census Region %"
New England
Mid-Atlantic
South-Atlantic
East Central North
East Central South
West Central North
West Central South
Mountain
Pacific
Dialysis characteristic %
Twice weekly dialysis"
High flux (KUF> 20)"
Temporary vascular access
Hospital facility"
Outcome measures
Died %
Transplanted following start of study %
Days to death or censoring mean
Sample size total
Prevalent > 1 year
Incident in 1990
"Analysis & Excluded Sample are bicarbonate dialysate
prevalent > 1 yearbAnalysis Sample excludes patients without a post-dialysis BUN value,
patients with 2 or 4 sessions per week, and patients missing information on
at least half comorbid conditions
"From the USRDS database
"See Reference 26
"Variable not used as a covariate in the main analysis
of the geographic distribution of dialyzer membranes and deliv-
ered dose of dialysis, suggested that regional differences exist. All
proportional hazards analyses were therefore stratified (SAS 6.07)
[25] by the nine Census Regions [261.
Additional sensitivity analyses used stratification by sampled
dialysis unit to control for possible "center effects" in estimating
the slope of dose with mortality. Diabetic status was the focus of
several analyses. These analyses included stratification by the
presence of diabetes (either as the primary cause of ESRD or as
a comorbid factor), as well as separate proportional hazards
models separately for diabetic and non-diabetic patients. Addi-
tional analysis tested if the effect of dose of dialysis varied
significantly by the presence of diabetes.
In order to identify the dose level (URR or Kt/V) beyond which
there is no beneficial effect on mortality of increasing dialysis
dose, proportional hazards models were fitted using a linear slope
change model (spline function) [27] at each of several predeter-
mined cut points. These statistical models test whether a horizon-
tal line (slope = 0) relating dialysis dose (URR or Kt/V) and log(risk of death) at dose values above the cut point would give a
significantly better fit to the data. The 95% confidence interval
(CI) for the dose above which the slope changed to 0 (that is, no
relationship) was calculated based on the likelihood ratio test.
The 95% confidence interval includes all dose values which were
not rejected at the 5% level.
Results
Table 1. Descriptive statistics
58.0
4.5
60.5
32.6
6.9
47.0
53.0
13.6
67.1
166.7
24.0
27.0
25.6
16.1
30.3
16.9
9.0
15.7
41.8
45.6
37.4
44.5
10.1
23.1
3.71
177.3
77.3
n/a
0.50
0.9
9.9
14.0
15.4
5.9
8.8
11.0
7.8
26.2
57.8
4.6
58.0
38.6
4.4
50.0
50.0
11.3
69.3
167.8
24.6
25.0
28.7
15.5
30.6
19.7
7.5
17.2
44.0
48.3
43.7
49.7
8.9
22.8
3.80
178.4
76.4
30.6
0.51
6.7
16.2
23.6
11.9
10.4
7.7
11.0
3.5
8.6
n.a.
19.5
2.3
4.2
30.0
7.3
509
2,311
2,311
0
Basic descriptive statistics for all covariates used in the analysis
are presented in Table 1. (Factors not used as covariates in the
proportional hazards modeling are indicated with a superscript e.)
Two subsamples are shown, both on ESRD therapy for more than
one year and receiving bicarbonate dialysis. The first is the
Analysis Sample of 2,311 patients for whom we had available
information on the delivered dialysis dose. The second is the
subsample of 1,713 patients who were matched to the USRDS
data base, but were excluded from the analysis primarily because
the dose of delivered dialysis could not be calculated. A compar-
ison of these two subsamples suggests that they are similar except
for differences in geographic distribution. A proportional hazards
test for differences in patient mortality between the two sub-
samples showed that the Excluded Sample had a reported relative
7 2
risk of 1.04 compared to the Analysis Sample, but this was
183 statistically insignificant (P = 0.55). Thus, covariate controls and
3:1 stratification by geographic region help to make the results
6.5 generalizable beyond the Analysis Sample.
Prescribed Kt/V (data not shown) averaged 1.08, which is within
32.1 2% of the average delivered Kt/V of 1.10 [5]. URR averaged
499:6 60.1%.
1,720 Shown in Figures 1 and 2 are results of the four main analyses
1,720 estimating the relationship of delivered dose (URR in Fig. 1 and
0 Kt/V in Fig. 2) and relative mortality risk. All four analyses use a
only and proportional hazards model with 21 covariates and stratification
by geographic region. The two bar charts represent categorical
estimates of the correlation of dialysis dose and mortality. The
two line charts presented as insert in Figures 1 and 2 represent
separately estimated continuous linear specifications of the cor-
relation of dose with mortality. The line chart in Figure 1 indicates
that a 5 percentage point higher URR (such as 65% vs. 60%) is
associated with an 11% lower mortality risk (RR = 0.89, P =
0.001). Using Kt/V as a measure of dialysis dose indicates that a
Fig. 1. The relative risk of mortality by delivered
dose of dialysis measured as Urea Reduction
Ratio (in percent) among a random sample of
U.S. patients prevalent on dialysis for more than
one year on Dec. 31, 1990 (N = 2,311). The line
represents the relationship of delivered URR
and mortality risk, with URR as a continuous
variable and with the mean URR (60.1) set as
the reference (RR = 1.00). The thin portion of
the line indicates the segment in which the
correlation may be less steep. The bars
represent the risk of mortality for different
categories (quintiles) of delivered URR with
URr = 58.8 to 62.4 arbitrarily set as the
reference (RR = 1.00). *From the pre/post-
BUN and pre/post-weight. N = 2,311, thrice
weekly only.
Fig. 2. The relative risk of mortality by delivered
dose of dialysis (measured as Daugirdas corrected
Kt/V) among a random sample of US. patients
prevalent on dialysis for more than one year on
Dec. 31, 1990 (N = 2,311). The line represents
the relationship of delivered KtIV and mortality
risk, with Kt/V as a continuous variable and
with the mean Kt/V (1.10) set as the reference
(RR = 1.00). The thin portion of the line
indicates the segment in which the correlation
may be less steep. The bars represent the risk
of mortality for different categories of delivered
KtIV with Kt/V = 1.0—1.2 arbitrarily set as the
reference (RR = 1.00). *FrOm (1
post/pre)BUN. N = 2,311, thrice weekly.
0.1 higher KtIV is associated with a 7% lower mortality risk
(RR 0.93, P = 0.01). The correlation of Kt/V and URR was
very high (r = 0.96), and therefore the similarity of the two
continuous estimates of the correlation of dose with mortality
would be expected.
The categorical estimates in Figures 1 and 2 are compared to
the mortality risk experienced by the middle quintile group (ref =
1.00) and show a clear downward trend in mortality with higher
doses of delivered therapy. Generally, the categorical results were
very consistent with the linear models, and yielded statistically
significant results at either extreme of dose.
In sensitivity analyses, we changed the acceptable range of Kt/V
from 0.4 to 2.0 to narrower ranges of 0.6 to 1.6 and 0.4 to 1.6. The
linear relationship between mortality risk and Kt/V remained
statistically significant (P < 0.001 for both) and appeared to be
stronger with 9% lower mortality risk per 0.1 higher KtIV (RR =
0.91).
The impact of "skipped" dialysis treatments on reducing the
mortality dialysis dose was assessed by adding a covariate for this
occurrence during the first month of study. Although "skipped"
treatments did not affect the slope of the mortality curves shown
in Figures 1 and 2, the measured mortality risk associated with
"skipped" treatments supports the general finding that a lower
dialysis dose implies higher mortality. One "skipped" treatment in
a month of 13 treatments yields an 8% reduction in the monthly
Kt/V and accounted for a 14% higher mortality risk (RR = 0.01).
By comparison the slope of the linear estimates of Kt/V and
mortality in Figure 2 would imply a substantially lower impact of
one skipped treatment. This suggests that the effect of a missed
treatment was approximately twice the linear effect reported in
Figure 2.
To identify the dialysis dose level beyond which there is no
beneficial effect of increasing dose, proportional hazards models
(one for each indicator of dialysis dose) were fitted using a linear
slope change model 27) at each of several predetermined cut
points. A range of potential cut points were considered, with a
horizontal line (slope = 0) above the cut point, for the linear
relationship between dose and log (risk of death). The models
with the best fit had a horizontal relationship above 70% for URR
and 1.3 for Kt/V, respectively. The slopes below these points were
steeper than those reported in the primary analyses with a
reduction in mortality risk by 9% per 0.1 Kt/V or 12% per 5
1.5
1.0
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0.5
0.0
<53.4 53.4—58.7 58.8—62.4 62.5—67.0 > 67.0
Urea reduction ratio*, %, quintiles
1.5
1.0
0.5
0.0 1pi116
<0.91 0.91—1.05 1.06—1.16 1.17—1.32 1.33 +
Delivered Kt/V*, quintiles
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percentage points higher URR. Allowing the slope to be 0 above
these values (that is, Kt/V of 1.3 or URR of 70%) led to a
marginally significant improvement in the fit of the overall model
(P = 0.065) without accounting for the multiple tests that were
performed to select the best model. If there is a horizontal
relationship we are 95% confident that it starts no lower than a
Kt/V of 1.15 or a URR of 62%. This 95% confidence interval has
no upper bound because the improvement in fit with the slope
change model was not significant at a P value of less than 0.05.
Sensitivity analyses
Several different specifications of models were tested as a prior
study has suggested that death rates of diabetics and non-diabetics
are not proportional, which would violate the basic assumption of
proportional hazards. Patient diabetic status was added as a
stratification parameter along with geographic region. The linear
estimate of the relative mortality with Kt/V was very similar to the
estimate presented in Figure 2.
In addition to stratification on diabetic status, separate models
were estimated for diabetic and non-diabetic patients. The esti-
mated RR of mortality, per 0.10 higher KtIV, was 0.907 for
diabetic patients (P < 0.001) and 0.952 for non-diabetic patients(P = 0.048). These sensitivity estimates suggest that KtIV and
mortality may have a steeper slope for diabetics than for non-
diabetics (RR = 0.907 vs. 0.952) but the slopes were not statisti-
cally different from each other (P = 0.18). A final test of sensitivity
of the influence of diabetes was to estimate an interaction effect
between KtIV and diabetic status. This test was not statistically
significant (P = 0.83).
Additional sensitivity analyses tested the influence of dialyzer
membrane (categorized as cellulose, modified cellulose, and
synthetic) on estimates of the impact of Kt/V on mortality. The
type of dialyzer membrane did not significantly modify the
association of Kt/V with mortality as reported in Figures 1 and 2,
although the type of dialyzer membrane appeared to have some
influence; this is the subject of our ongoing research [28, 29]. The
sensitivity test for center effects suggested that some of the
apparent effect of dialysis dose on mortality may be explained by
a general center effect.
An alternative specification of one of the main models (linear
estimate using URR) was estimated using as indicators of the
dialysis dose four separate measurements: prescribed sessions per
week, prescribed minutes per session, URR and percentage
weight change. Of the four measures, only URR was statistically
significant in association with mortality (P = 0.001) and quanti-
tatively similar to the estimates reported in Figure 1. The effect of
prescribed treatments per week on mortality was protective
(RR = 0.93 per session; P = 0.60). At the same URR, the effect
of prescribed minutes per session on mortality was quantitatively
small and possibly adverse although statistically insignificant (P =
0.62). A greater weight change during dialysis appeared adverse
but far from significant (P = 0.71).
Finally, the quantitative effects of comorbid conditions on
patient mortality were similar to those previously reported [221.
Statistically significant and quantitatively notable effects on mor-
tality (not shown) included age, race, diabetes, nutritional status
(both undernourished and serum albumin), inability to ambulate,
congestive heart failure, coronary heart disease, cerebrovascular
disease, peripheral vascular disease, and chronic obstructive pul-
monary disease. Comorbid factors that were not statistically
significant (P > 0.05) were: cirrhosis, neoplasms, smoking, biliru-
bin, cholesterol, obesity, and left ventricular hypertrophy.
To determine if the 18 comorbid factors might confound the
estimation of the association of mortality with dialysis dose, an
analysis was performed using only age, sex, race, and cause of
ESRD as covariate controls. With this shortened list of covariates
the estimated mortality risk was 12.6% lower per 5 percentage
point higher URR compared to 11% lower in the complete
model.
Discussion
The statistical results reported in this study provide a strong
indication that higher doses of dialysis are associated with lower
levels of mortality. This analysis of dialysis dose has several
features that make this paper unique. This is the first paper to use
a randomly selected national sample of all Medicare patients.
Secondly, this is the first report to control for such a long list of
covariates. Thirdly this analysis used two alternative measures of
the dialysis dose, URR and Kt/V. The two linear estimates (Figs.
1 and 2) provide good approximations of the categorical estimates
shown in the same Figures. The categorical estimates do not
impose a constraint on the functional form of the relationship.
These linear estimates of a 7% lower mortality risk per 0.10 higher
KtIV and 11% lower mortality risk per 5 percentage points higher
URR are similar to the estimates provided by Owen et al [3]. The
conclusions of this analysis clearly support the results of previous
studies and provide a more precise relationship between the dose
of dialysis and mortality.
This study clearly shows the close correspondence between the
two dialysis dose measures URR and Kt/V for use in population
based analyses of mortality. Since both dialysis dose measures are
either totally or mostly derived from pre- and post-dialysis BUN,
this should not be a surprise (the correlation coefficient between
Kt/V and URR was 0.96).
One can assume that at very high delivered dialysis dose, (more
replacement of renal function), a smaller benefit may be achieved
per unit of increase in dose. The current study suggests that the
dose where the slope of the mortality by dose curve turns flat
occurs near a URR of 70% or a Kt/V of 1.3. This analysis also
indicated that up to a URR of 70% and a Kt/V of 1.3, the slope
was linear and somewhat steeper than shown in Figures 1 and 2
for all ranges. We note that analysis of NCDS data suggested no
relationship of mortality to dose above a KtIV of 1.0 [2], although
this estimate was challenged by Keshaviah [30]. Both the linear
and categorical estimates reported in Figures 1 and 2 suggest that
a substantial reduction in mortality risk (approximately 20%) may
be possible at a delivered therapy of 1.3 versus 1.0 Kt/V (URR of
70 vs. 60%). Owen et al [3] estimate that the mortality curve turns
flat above a URR of 65%. Given the wide confidence interval, our
estimate of 70% URR is consistent with Owen et al [31.
As recently reported [14] the dose of delivered hemodialysis
therapy (Kt/V) provided to US patients fell short of the dose of
dialysis derived from the National Cooperative Dialysis Study [2].
Thirty-eight percent of patients who had been on dialysis for at
least one year were receiving a Kt/V of 1.0 or less in 1991. The
NCDS suggested a minimum dose of 1.0 to achieve satisfactory
short-term outcome.
This low dose of delivered dialysis probably results from several
factors. Perhaps the most important is that the dose of dialysis was
not routinely measured until recently. There are indications that
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the dose of dialysis continues to improve [23, 31, 32]. In 1986 to
1987, the time of the former USRDS study of delivered dialysis
therapy, only 10% of the incident patients had a pre and post
BUN [14], a necessary requirement for calculating delivered
dialysis dose. For the 1991 prevalent patients of the present study,
the fraction of patients with a pre- and post-BUN has increased to
55%. This has to be seen as a substantial improvement in
treatment monitoring.
Prescribed treatment time was not found to be either qualita-
tively plausible or statistically significant in explaining mortality
when controlling for dose of dialysis. While this finding appears to
be consistent with Owens et al [3], future studies should obtain
data on the actual rather than prescribed duration of the dialysis
treatment.
The analyses also indicate a substantial geographic variation in
the practice of measuring the dose of dialysis in 1991. By Census
Region (Table 1) and by Network (not shown), it is clear that at
the time of the current study there was substantial variation in the
proportion of patients having their dose of dialysis monitored by
pre and post dialysis BUN measurements.
This paper reports for the first time on the impact of "skipped"
dialysis treatments on patient survival. Our analyses suggest that
the results of each "skipped" treatment per month confirm the
general finding that lower dose correlates with higher mortality.
The quantitative effect of the skipped treatment appears to be
larger than the prorated monthly dose effect predicted by the
linear slope in Figure 2. It is likely that this larger effect of skipped
treatments may be the consequence of the fact that "skipping"
treatments might be an indicator for other adverse patient
behaviors, or that missed treatments result in more adverse effects
than simply a reduction in monthly dialysis dose.
Limitations of this research
Since there was no standardized procedure for timing and
techniques of collecting the post BUN sample, there is a potential
for non-comparable readings across dialysis facilities and patients.
While this type of error would usually lead to "errors in variables"
and bias towards no effect, the observed dialysis dose correlations
with mortality risk were strong and statistically significant. If there
is a bias in our results because of differences in post-dialysis BUN
collection, it probably leads to understating the correlation of
Kt/V with mortality. A suggestion for a steeper correlation was
provided in the sensitivity analysis which excluded the highest and
lowest KtIV ranges. Also reported above was a possible "center
effect" which could explain part of the apparent impact of higher
dose on patient mortality. Wolfe et al [33] have shown a significant
inverse correlation of the mean KtIV by facility with the facility
SMR. Thus, studies based on patients suggest that the center
effect level data and facility level data have consistently shown an
important role of the dialysis dose on mortality. All of these
studies are observational in design so some component of the
relationship could be due to either patient selection or center
effects.
This study did not account for the effects of residual renal
function as this datum was not collected. For this reason, we
selected patients who had been on dialysis for at least one year
(with the duration of prior ESRD averaging 4.6 years), under the
hypothesis that most patients would have little if any residual
renal function left after one year [21], Ideally, future analyses
should consider more direct measurements of residual renal
function.
The comorbid and risk factor measurements available to this
project include many measures of the presence but limited
indication of the severity of the comorbid condition. Future
analyses may include this additional detail, but it is unlikely to
substantially affect the current results. In the analysis of the
potential change in slope in the mortality risk by dialysis dose the
break point was selected statistically from among several possible
values. The validity of this marginally significant slope change
estimate should be tested in the future with data that include a
larger fraction of patients receiving a high dialysis dose.
In conclusion, this national study of a large random sample of
U.S. hemodialysis patients shows a large and statistically signifi-
cant inverse correlation of the delivered dose of dialysis and
mortality risk, A strength of this study is that it adjusted for
numerous comorbidity and risk factors. Sensitivity analyses show
that the estimated linear slope of dialysis dose and mortality is
robust and remarkably stable to numerous alternative specifica-
tion of the main effect. Survival benefits from higher dialysis dose
appear to be present up to a Kt/V level of approximately 1.3, with
a 7% lower mortality risk per 0.1 higher KtIV and an 11% lower
mortality risk per 5 percentage points higher URR. Future studies
may document an even larger benefit through more accurate
determination of dialysis dose.
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